par Judd, Ali;Marques, Laura;Collins, Intira Jeannie;Gibb, Diana;González Tome, Maria Isabel;Navarro, Marisa;Warszawski, Josiane;Königs, Christoph;Spoulou, Vana;Prata, Filipa;Chiappini, Elena;Chappell, Elizabeth;Naver, Lars;Giaquinto, Carlo;Thorne, Claire;Marczynska, Magdalena;Okhonskaia, Liubov;Posfay-Barbe, Klara;Ounchanum, Pradthana;Techakunakorn, Pornchai;Kiseleva, Galina;Malyuta, Ruslan;Turkova, Anna;Volokha, Alla;Ene, Luminita;Goodall, Ruth;Le Coeur, Sophie;Noguera-Julian, Antoni;Goetghebuer, Tessa ;Doerholt, Katja;Galli, Luisa;Pajkrt, Dasja
Référence PLoS medicine, 15, 1, e1002491
Publication Publié, 2018-01
Référence PLoS medicine, 15, 1, e1002491
Publication Publié, 2018-01
Article révisé par les pairs
Résumé : | Background: Published estimates of mortality and progression to AIDS as children with HIV approach adulthood are limited. We describe rates and risk factors for death and AIDS-defining events in children and adolescents after initiation of combination antiretroviral therapy (cART) in 17 middle- and high-income countries, including some in Western and Central Europe (W&CE), Eastern Europe (Russia and Ukraine), and Thailand. Methods and findings: Children with perinatal HIV aged <18 years initiating cART were followed until their 21st birthday, transfer to adult care, death, loss to follow-up, or last visit up until 31 December 2013. Rates of death and first AIDS-defining events were calculated. Baseline and time-updated risk factors for early/late (≤/>6 months of cART) death and progression to AIDS were assessed. Of 3,526 children included, 32% were from the United Kingdom or Ireland, 30% from elsewhere in W&CE, 18% from Russia or Ukraine, and 20% from Thailand. At cART initiation, median age was 5.2 (IQR 1.4–9.3) years; 35% of children aged <5 years had a CD4 lymphocyte percentage <15% in 1997–2003, which fell to 15% of children in 2011 onwards (p < 0.001). Similarly, 53% and 18% of children ≥5 years had a CD4 count <200 cells/mm3in 1997–2003 and in 2011 onwards, respectively (p < 0.001). Median follow-up was 5.6 (2.9–8.7) years. Of 94 deaths and 237 first AIDS-defining events, 43 (46%) and 100 (42%) were within 6 months of initiating cART, respectively. Multivariable predictors of early death were: being in the first year of life; residence in Russia, Ukraine, or Thailand; AIDS at cART start; initiating cART on a nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimen; severe immune suppression; and low BMI-for-age z-score. Current severe immune suppression, low current BMI-for-age z-score, and current viral load >400 c/mL predicted late death. Predictors of early and late progression to AIDS were similar. Study limitations include incomplete recording of US Centers for Disease Control (CDC) disease stage B events and serious adverse events in some countries; events that were distributed over a long time period, and that we lacked power to analyse trends in patterns and causes of death over time. Conclusions: In our study, 3,526 children and adolescents with perinatal HIV infection initiated antiretroviral therapy (ART) in countries in Europe and Thailand. We observed that over 40% of deaths occurred ≤6 months after cART initiation. Greater early mortality risk in infants, as compared to older children, and in Russia, Ukraine, or Thailand as compared to W&CE, raises concern. Current severe immune suppression, being underweight, and unsuppressed viral load were associated with a higher risk of death at >6 months after initiation of cART. |